KMT2B

Across TCGA pan-cancer cohorts, KMT2B mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of KMT2B’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where KMT2B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KMT2B is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

LSCC, COAD, and CCRCC are the cancer types where KMT2B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KMT2B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.375	<.001	8	view →
COAD	Female	II,III,IV	−0.987	<.001	7	view →
CCRCC	Male	All	+0.250	<.001	6	view →
LUAD	Female	All	+0.263	<.001	5	view →
PDAC	Female	III,IV	+0.424	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

KMT2B–LSCC

Open the LSCC breakdown →